SCHEMBL7946790

SCHEMBL7946790

Nc1ncccc1NCc1cc(NC(=O)c2cc3cc(Br)ccc3o2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.55
NPC1 O15118 7/20 0.55
KMT2A Q03164 6/20 0.55
POLB P06746 4/20 0.55
TSHR P16473 3/20 0.44
MEN1 O00255 3/20 0.44
TP53 P04637 3/20 0.44
MAPK1 P28482 1/20 0.44
NLRP3 Q96P20 1/20 0.44
MAPT P10636 3/20 0.43
BACE1 P56817 3/20 0.42
RXFP1 Q9HBX9 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 2/20 0.41
BCAT1 P54687 1/20 0.41
F12 P00748 1/20 0.41
BLM P54132 1/20 0.41
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7946768 0.89 NPC1 (0.47) RAB9ANPC1KMT2APOLBTSHR
SCHEMBL7941949 0.89 NPC1 (0.55) RAB9ANPC1KMT2ATSHRMEN1
SCHEMBL7940374 0.88 RAB9A (0.58) RAB9ANPC1KMT2APOLBTSHR
SCHEMBL7944993 0.87 HPGD (0.49) RAB9ANPC1KMT2APOLBTSHR
SCHEMBL7941526 0.85 RAB9A (0.52) RAB9ANPC1KMT2APOLBTSHR
SCHEMBL7934104 0.84 RAB9A (0.47) RAB9ANPC1KMT2APOLBTP53
SCHEMBL7939328 0.84 ALDH1A1 (0.49) RAB9ANPC1KMT2APOLBTSHR
SCHEMBL7945393 0.83 RAB9A (0.58) RAB9ANPC1KMT2APOLBTSHR
SCHEMBL7940417 0.82 HPGD (0.48) RAB9ANPC1POLBTSHRTP53
SCHEMBL7941381 0.81 BACE1 (0.52) BACE1PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 RAB9A 1287/4885NPC1 431/4885KMT2A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.